Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Online download statistics by month:

Online download statistics by month: April 2022 to November 2023

	Abstract	Full	Pdf
Apr 2022	564	583	248
May 2022	415	425	172
Jun 2022	198	204	73
Jul 2022	138	148	42
Aug 2022	150	150	40
Sep 2022	219	221	55
Oct 2022	188	192	56
Nov 2022	132	132	36
Dec 2022	127	128	40
Jan 2023	118	119	32
Feb 2023	92	93	34
Mar 2023	91	92	38
Apr 2023	80	80	31
May 2023	95	95	29
Jun 2023	95	96	24
Jul 2023	65	67	21
Aug 2023	92	93	15
Sep 2023	86	86	16
Oct 2023	83	83	24
Nov 2023	97	100	18
Total	3125	3187	1044